相关实验视频

Updated: Sep 14, 2025

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Published on: May 20, 2014

在低度血清性卵巢癌中RAS-MEK-ERK通路

Elizabeth H Stover¹, Elizabeth K Lee¹, Geoffrey I Shapiro¹

¹Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, United States of America; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, United States of America.

Gynecologic oncology

|July 18, 2025

概括

低度血清性卵巢癌 (LGSC) 是由RAS-MEK-ERK通路突变驱动的. 通过MEK抑制剂和新型KRAS抑制剂向这种途径,有望改善LGSC治疗结果.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一个

背景情况:

低度血清性卵巢癌 (LGSC) 是一种不常见的上皮性卵巢癌亚型.
LGSC通常发生在年轻患者身上,对基化疗敏感性有限.
基因组研究显示,LGSC和血清边缘瘤 (SBT) 中经常出现RAS-MEK-ERK通路突变.

研究的目的:

审查RAS-MEK-ERK途径在LGSC中的作用.
总结当前和新兴的针对性治疗策略LGSC.
突出新型抑制剂在LGSC治疗中的潜力.

主要方法:

对鉴定LGSC中RAS-MEK-ERK通路突变 (KRAS,NRAS,BRAF) 的基因组研究的审查.
对LGSC中MEK抑制剂 (例如,美丁尼,比尼米丁尼) 的临床试验数据的分析.
检查正在进行的针对新型向疗法的研究,包括RAF/MEK和KRAS抑制剂.

主要成果:

像特拉美丁尼布这样的MEK抑制剂在复发的LGSC中显示出临床益处.
一些MEK抑制剂在具有KRAS突变的瘤中显示出更高的响应率,尽管疗效可能是可变的.
新兴疗法,如阿图托美提尼布/德法提尼布和新型KRAS抑制剂正在研究中.

结论:

RAS-MEK-ERK通路是LGSC的一个关键治疗点.
向疗法,包括MEK抑制剂和新型KRAS抑制剂,为LGSC提供了有前途的新治疗途径.
持续的临床和翻译研究对于优化RAS-MEK-ERK通路抑制策略至关重要.

关键词:

低级血清性卵巢癌是低级的卵巢癌.在 RAS 路径上.有针对性的治疗.

更多相关视频

In vitro Mesothelial Clearance Assay that Models the Early Steps of Ovarian Cancer Metastasis

In vitro Mesothelial Clearance Assay that Models the Early Steps of Ovarian Cancer Metastasis

Published on: February 17, 2012

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

MAPK Signaling Cascades

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Interactions Between Signaling Pathways

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...